Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Brain Cancer|Non-Small-Cell Lung Cancer
Phase 2: Brain Cancer|Multiple Myeloma|Lymphoma, Non-Hodgkin|Melanoma|Renal Cell Carcinoma|Gliosarcoma|Breast Cancer|Adenocarcinoma|Glioma|Lymphocytic Chronic B-Cell Leukemia|Glioblastoma|Non-Small-Cell Lung Cancer|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Brain Stem Cancer
Phase 1: Glioma|Prostate Cancer|Breast Cancer|Astrocytoma|Oligodendroglioma|Glioblastoma|Colorectal Cancer|Intestinal Diseases|Prostatic Diseases|Intestinal Cancer|Myelodysplastic-Myeloproliferative Diseases|Rectal Diseases|Plasmacytoma|Multiple Myeloma|Head and Neck Cancer|Breast Diseases|Lung Cancer|Myeloproliferative Disorders|Leukemia, Plasma Cell|Gastrointestinal Cancer|Bronchogenic Carcinoma|Squamous Cell Carcinoma|Oropharyngeal Cancer|Non-Small-Cell Lung Cancer|Laryngeal Cancer|Hypopharyngeal Cancer|Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
A6701QIBA | N/A |
Unknown status |
Prostate Cancer |
2022-12-01 |
|
NCI-2009-01092 | P2 |
Completed |
Glioblastoma|Gliosarcoma |
2011-02-16 |
|
NCI-2012-01829 | P2 |
Completed |
Glioma |
2010-04-01 |
|
PCYC-0222 | P2 |
Terminated |
Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-02-01 |
|
PCYC-0229 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-02-01 |
|
PCYC-0228 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-01-01 |
|
PCYC-0227 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2007-06-01 |
|
NCI-2012-01845 | P1 |
Completed |
Glioma |
2007-03-01 |
|
PCYC-0223 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia |
2007-02-01 |
|
NU 02H8 | P2 |
Terminated |
Lymphoma, Non-Hodgkin |
2007-01-01 |
|
NCI-2012-02607 | N/A |
Terminated |
Soft Tissue Cancer|Pancreatic Cancer|Liver Cancer|Non-Small-Cell Lung Cancer|Gastrointestinal Stromal Tumors|Germinoma|Uterine Cancer|Cholangiocarcinoma|Colorectal Cancer|Bile Duct Cancer|Adenocarcinoma|Gastrointestinal Cancer|Appendiceal Cancer|Embryonal Carcinoma|Ovarian Cancer|Carcinoid Tumor|Malignant Carcinoid Syndrome|Gallbladder Cancer|Leiomyosarcoma|Fallopian Tube Cancer|Peritoneal Cancer|Lymphoma |
2006-01-01 |
|
CDR0000069322 | P1 |
Completed |
Lung Cancer|Lymphoma|Intestinal Diseases|Rectal Diseases|Plasmacytoma|Multiple Myeloma|Intestinal Cancer|Prostatic Diseases|Head and Neck Cancer|Breast Diseases|Colorectal Cancer|Myeloproliferative Disorders|Breast Cancer|Leukemia, Plasma Cell|Prostate Cancer|Myelodysplastic-Myeloproliferative Diseases |
2005-10-01 |
|
MSKCC-01051 | P2 |
Completed |
Glioblastoma|Brain Stem Cancer |
2003-04-01 |
|
SMART | P3 |
Completed |
Brain Cancer|Non-Small-Cell Lung Cancer |
None |
|
PCYC-0224 | P2 |
Terminated |
Brain Cancer|Melanoma|Breast Cancer |
None |
|
PCYC-0215 | P2 |
Completed |
Multiple Myeloma |
None |
|
PCYC-0219 | P2 |
Completed |
Renal Cell Carcinoma |
None |
|
PCYC-0214 | P1 |
Completed |
Prostate Cancer|Breast Cancer |
None |
|
PCYC-0218 | P1 |
Completed |
Astrocytoma|Oligodendroglioma|Glioblastoma |
None |
|
PCYC-0216 | P2 |
Terminated |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
None |
|
PCYC-0212 | P1 |
Completed |
Breast Cancer|Gastrointestinal Cancer|Prostate Cancer |
None |
|
PCYC-0221 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
|
PCYC-0220 | P1 |
Completed |
Bronchogenic Carcinoma|Non-Small-Cell Lung Cancer |
None |
|
PCYC-0210 | P1 |
Terminated |
Squamous Cell Carcinoma|Oropharyngeal Cancer|Head and Neck Cancer|Laryngeal Cancer|Hypopharyngeal Cancer |
None |